Monitor for any future amendments that disclose a change in purpose or new activist demands; the current filing is purely administrative and does not alter the investment thesis.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 3 $5.74entry
- T+1 · 13d ago −1.05%α −2.70% · $5.68
- T+5 · 7d ago −5.14%α −4.55% · $5.45
- T+9 · todayOpen
- T+20 · in 15d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Frazier Life Sciences filed Amendment No. 12 to its Schedule 13D for Phathom Pharmaceuticals, reporting aggregate beneficial ownership of approximately 12.5 million shares (about 15.4% of outstanding common stock, including warrants subject to beneficial ownership limitations). The filing is a routine periodic update with no change in purpose or demands; it reflects the group's ongoing passive investment and does not signal escalation or de-escalation.
Key Financial Metrics
Key Facts
- Frazier Life Sciences Public Fund, L.P. directly holds 5,323,356 shares (6.5% of outstanding).
- Frazier Life Sciences IX, L.P. directly holds 5,827,415 shares (7.2%).
- Frazier Life Sciences XI, L.P. directly holds 980,286 shares (1.2%).
- Frazier Life Sciences X, L.P. directly holds 59,403 shares (0.1%).
- Frazier Life Sciences XII, L.P. directly holds 276,029 shares (0.3%).
- James N. Topper beneficially owns 6,013,327 shares (7.4%), including options and shares held by affiliated funds.
- Patrick J. Heron beneficially owns 5,901,756 shares (7.3%), including shares held by affiliated funds.
- The group holds warrants to purchase additional shares, subject to 9.99% and 19.99% beneficial ownership limitations.
- The filing is an administrative amendment updating address and citizenship information; no new demands or strategic changes were disclosed.
Financial Impact
No material financial impact; the filing reflects existing ownership levels with no new transactions or changes in strategy.
Risk Factors
- No new risks identified; the filing is a routine periodic update.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13D/A Filing (Primary) | 0001231919-26-001523 |
| Document: 0001231919-26-001523-index-headers.html | 0001231919-26-001523 |
| Document: 0001231919-26-001523-index.html | 0001231919-26-001523 |
| Document: 0001231919-26-001523.txt | 0001231919-26-001523 |
Track record
16 reports on PHAT
3 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +36.43% at T+60 after the Jul 30, 2026 report. 3 of 5 went positive at some point.
Filters
- Nov 10, 20266d ago SC 13G/A Neutral 2/10 Entry $6.28 Now $5.88 −6.37% settles Nov 18
- Nov 2, 202614d ago SC 13D/A Neutral 3/10 Viewing Entry $5.74 to $5.45 Now $5.88 +2.44% ▼ −5.14% −4.55% vs SPY
- Oct 29, 202618d ago 8-K Bullish 6/10 No price data
- Oct 29, 202618d ago Press Release Bullish 5/10 Entry $6.22 to $5.08 Now $5.88 −5.47% ▼ −18.33% −13.60% vs SPY
- Oct 26, 202621d ago 8-K Bearish 5/10 Entry $5.94 to $5.74 Now $5.88 +1.01% ▲ +3.37% +2.11% vs SPY
- Oct 23, 202624d ago 8-K Bearish 6/10 Entry $5.94 to $5.74 Now $5.88 +1.01% ▲ +3.37% +2.11% vs SPY
- Oct 19, 202628d ago Press Release Neutral 1/10 Entry $7.01 Now $5.88 −16.12% No price data
- Sep 29, 20266w ago 8-K Neutral 4/10 Entry $7.30 to $6.81 Now $5.88 −19.45% ▼ −6.71% −8.63% vs SPY
- Jul 30, 202615w ago 8-K Mixed 5/10 No price data
- Jul 30, 202615w ago Press Release Bearish 6/10 Entry $9.03 to $8.39 Now $5.88 +34.88% ▲ +7.09% +10.71% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers